Papillary fibroelastomas (PFE) are benign neoplasms with little available outcome data. Mayo Clinic researchers conducted a study published in the Journal of the American College of Cardiology to describe the frequency and clinical course of patients with surgically removed PFE and echocardiographically suspected, but unoperated, PFE.
Amyloidosis derived from leukocyte cell-derived chemotaxin 2 (ALECT2), a newly recognized form of amyloidosis, has already been established as a frequent form of systemic amyloidosis in the United States, with predominant involvement of the kidney and liver. Mayo Clinic researchers reviewed recent Mayo Clinic and non-Mayo Clinic studies to establish the clinicopathologic characteristics, incidence, and outcome of amyloidosis derived from ALECT2.
Dabigatran etexilate (Pradaxa), an oral, direct thrombin inhibitor, was approved in October 2010 by the U.S. Food and Drug Administration (FDA) for prevention of stroke and thrombosis in patients with nonvalvular atrial fibrillation (AF). In a recent article in Clinical Chemistry, Mayo Clinic researchers, Hemamalini Ketha, Ph.D., and John Mills, Ph.D., discuss whether dabigatran is a risk to patient safety.
Platelet Function Tests: Precision and Reliability in Healthy Volunteers and Donors on Daily Antiplatelet Agent Therapy
Protocols for Mechanical Circulatory Support (MCS) often call for monitoring and titration of antiplatelet agents in the perioperative period. In this “Hot Topic,” Brad Karon, M.D., Ph.D., describes a study to identify the optimal platelet function tests for this purpose.
Mayo Clinic’s launch of eight new next-generation sequencing (NGS) panels is intended to improve the lives of patients and families living with inherited cardiac conditions by aiding in the diagnosis and management of these complex disorders. These disorders include hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, Noonan syndrome, Marfan syndrome, long QT syndrome, and Brugada syndrome.
A recent article in Clinical Lab Products, discusses various lipid screening approaches for cardiovascular disease, including Mayo Clinic's use of Helena's Spife system for the determination of Lp(a) levels.
Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is common and increasing in prevalence. Mayo Clinic researchers conducted a study in Circulation to test the hypothesis that cardiac hypertrophy, microvascular rarefaction and myocardial fibrosis are common and related in patients with HFpEF.
LDL cholesterol (LDL-C)3, an important modifiable risk factor for atherosclerotic cardiovascular disease, is primarily calculated via the Friedewald equation. However, a newly derived equation for LDL-C estimation was recently published that addressed limitations in the commonly used Friedewald LDL-C calculation method. Mayo Clinic researchers completed a study to evaluate the performance of a novel method to classify patients with superior concordance to measured LDL-C compared to the Friedewald method.
Lupus anticoagulants are associated with thrombosis, recurrent fetal loss, neurological problems, and cutaneous manifestations. Accurate diagnosis is important considering the potential use of long-term anticoagulant therapy because of the high risk of recurrent thrombosis.
Nuclear Magnetic Resonance (NMR) Lipoprotein Particle Testing Using LipoScience Vantera® Clinical Analyzer Now Performed at Mayo Medical Laboratories
Mayo Medical Laboratories is now performing NMR lipoprotein particle testing using the LipoScience, Inc. Vantera® Analyzer, which identifies and quantifies concentrations of lipoproteins using NMR spectroscopy and proprietary signal processing algorithms. Read more for full details and test information.
Heart valve infections are one of the complications of implanted cardiac devices. Mayo Clinic's infectious disease experts are leaders in finding solutions to this problem, and their research has already changed medical practice and helped heart patients everywhere.
Heart failure mediated by elevated levels of a protein called galectin-3 affects between 30 percent and 50 percent of chronic heart failure patients and is associated with higher rates of mortality and rehospitalization. Mayo Medical Laboratories now offers galectin-3 testing to aid in the prognosis of patients diagnosed with chronic heart failure.